ZYBERNO
Stock Report
Updated Aug 30, 2026

Edgewise Therapeutics, Inc. (EWTX)

Healthcare • NASDAQ

$42.76

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Edgewise Therapeutics, Inc. (EWTX) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-39.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-43.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Edgewise Therapeutics, Inc. (EWTX) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:42.76
Market Cap:$4.60B

Valuation Multiples (2)

P/B Ratio:10.27x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$4.54B

Price Action & Momentum (3)

Momentum Percentile:97 / 100
% of 52-Week High:88.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-37.0%
Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-0.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$4.33
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-332.7%
Latest Earnings Filed:2026-08-06
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:16.24x
Quick Ratio:16.24x
Cash Ratio:2.49x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:442,476,000.00
Cash And Cash Equivalents:72,319,000.00
Long Term Debt:$2.57M
Net Debt:-$68.73M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$218.90M

Bottom Line Performance (3)

-$197.22M
Income Before Tax:-$167.80M
Ebitda Ttm:-216,787,000.00

Operating Expenses (5)

Operating Expenses:218,895,000.00
R And D Expense:171,273,000.00
Sga Expense:47,622,000.00
Income Tax Expense:$4.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$479.69M
Current Assets:$471.52M
Ppe Net:6,892,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:31,611,000.00
Current Liabilities:29,042,000.00
Long Term Debt:$2.57M
Short Term Debt:$1.02M

Equity & Capital (3)

Equity:$448.08M
Retained Earnings:-$652.71M
Common Stock:1,000,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:4,666,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:9,362,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$148.49M-$144.07M

Investment Activities (1)

Investing Cash Flow:$2.43M

Financing Activities (3)

Financing Cash Flow:$12.17M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:187,362,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,108,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.85
-$1.85
Earnings Per Share Ttm:-$1.83

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.34

Book Value & Capital (2)

Book Value Per Share:$4.16
Cash Per Share:0.67

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-0.5%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):18.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:EWTX
Company Name:Edgewise Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:107.67M
Shares Outstanding Basic:107.67M
Shares Outstanding Diluted:107.67M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 15:18:47 UTC
Data Timestamp:2026-08-30T15:18:47.830272
Scroll to Top